<DOC>
	<DOCNO>NCT00769522</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , cyclophosphamide , bendamustine , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . It yet know whether give fludarabine cyclophosphamide together rituximab effective give bendamustine together rituximab treat chronic lymphocytic leukemia . PURPOSE : This randomized phase III trial study fludarabine , cyclophosphamide , rituximab see well work compare bendamustine rituximab treat patient previously untreated B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>FCR BR Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To compare therapeutic efficacy fludarabine phosphate , cyclophosphamide , rituximab v bendamustine hydrochloride rituximab patient previously untreated B-cell chronic lymphocytic leukemia . - To compare incidence major side effect ( e.g. , myelosuppression ) associate regimens patient . - To compare rate infection secondary neoplasias patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord country disease stage . Patients randomize 1 2 treatment arm . - Arm I : Patients receive fludarabine phosphate IV cyclophosphamide IV day 1-3 . Patients also receive rituximab IV day 0 course 1 day 1 course 2-6 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive bendamustine hydrochloride IV day 1 2 . Patients also receive rituximab arm I . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients complete quality life questionnaire ( EORTC-C30 EURO-QOL ) baseline 12 , 24 , 36 , 48 , 60 month . After completion study therapy , patient follow every 3 month 2 year , every 6 month 3 year , year thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis Bcell chronic lymphocytic leukemia ( CLL ) meet 1 follow criterion : Binet stage C disease stage B A disease require treatment Binet stage B A disease meeting ≥ 1 following : Bsymptoms ( e.g. , night sweat , weight loss ≥ 10 % within past 6 month , fever &gt; 38°C 100.4°F ≥ 2 week without evidence infection ) constitutional symptom ( e.g. , fatigue ) Progressive lymphocytosis , define peripheral lymphocyte count &gt; 5 x 10^9/L ( i.e. , &gt; 50 % increase 2month period double peripheral blood lymphocyte count &lt; 6 month ) Evidence progressive marrow failure manifest development/worsening anemia and/or thrombocytopenia Massive , progressive , painful splenomegaly hypersplenism Massive lymph node lymph node cluster ( &gt; 10 cm long diameter ) progressive symptomatic lymphadenopathy No 17p deletion FISH No aggressive Bcell cancer , Richter syndrome PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy ≥ 6 month Total bilirubin ≤ 2 time upper limit normal ( ULN ) ( unless directly attributable CLL ) AST ALT ≤ 2 time ULN ( unless directly attributable CLL ) Creatinine clearance ≥ 70 mL/min ( creatinine clearance calculate patient serum creatinine ≥ 1.1 mg/dL ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study therapy Hepatitis B C negative HIV negative CIRS score &gt; 6 single score 4 one organ category No active secondary malignancy require treatment , except basal cell carcinoma malignant tumor curatively treat surgery , successfully treat secondary malignancy complete remission &gt; 5 year prior enrollment No history anaphylaxis follow exposure monoclonal antibody No active bacterial , viral , fungal infection No medical condition require prolong use oral corticosteroid ( i.e. , &gt; 1 month ) No cerebral dysfunction legal incapacity No circumstance would preclude completion study require followup PRIOR CONCURRENT THERAPY : No prior CLL specificchemotherapy , radiotherapy , and/or immunotherapy Prednisolone administer immediately prior initiation study therapy allow high lymphocyte count No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>